WALD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Waldencast PLC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is in a clear bearish trend, there is no strong proprietary buy signal, recent analyst targets have been cut, and the latest commentary points to slower growth and higher costs. I would not buy at the current price of $1.30; the better call is to wait for a stronger trend reversal and clearer fundamental improvement.
WALD is technically weak. The MACD histogram is negative and expanding, signaling downside momentum is still building. RSI_6 at 42.7 is neutral but leaning weak, so there is no oversold reversal confirmation yet. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which confirms the broader trend is down. Price at 1.30 is below the pivot at 1.39 and only slightly above support at 1.222, with the next lower support at 1.118 if selling continues. Overall, the chart does not support an immediate long-term buy.
Recent analyst notes still include Buy ratings from Alliance Global and Canaccord, which suggests some professionals see brand value in Obagi and Milk and possible upside from Saypha injectables. Analysts also see potential value in the valuation versus the brand portfolio. The stock-trend model suggests a possible 11.83% gain over the next month, indicating a chance of rebound if sentiment improves.
No news in the recent week means there is no fresh catalyst driving momentum. The stock fell 5.15% in regular trading, showing weak near-term sentiment. Analyst price targets were cut repeatedly, with Telsey lowering to $2 and Canaccord lowering to $2, while noting Q4 and FY25 results missed expectations and growth was slower than expected. EBITDA missed due to investment spending, and elevated costs tied to the SEC investigation and strategic review remain a drag. Hedge funds and insiders are neutral, so there is no sign of accumulating support. No recent congress or notable political trading data is available.
Latest quarter season: Q4. The latest quarterly results were weak, with EBITDA missing expectations and revenue/sales reported at $72M versus an estimated $76M. Analysts described the quarter as below expectations and noted slower-than-expected growth. The business is still in a transition period, with spending tied to the upcoming Saypha launch and elevated costs from the SEC investigation and strategic review. The balance sheet may be improving from the strategic review, but current financial trends are not strong enough to support a beginner-friendly long-term entry.
Analyst sentiment is mixed but clearly deteriorating on price targets. Alliance Global kept a Buy rating but cut its target to $2.50 from $3.50 after the Q4 report. Telsey cut its target to $2 from $3 and stayed Market Perform, citing disappointing Q4 results and slower growth. Canaccord also cut its target to $2 from $4 while keeping a Buy rating, noting sales missed estimates and costs remain elevated. Overall, Wall Street still sees some upside potential from the brands and pipeline, but the tone is cautious and the downward target revisions outweigh the bullish cases right now.
